Comparison between CT Scan Evaluation Criteria and PERCIST for Evaluation of Immune Check-Point Inhibitors Response

被引：0
|
作者：
Rossi, Giovanni [1 ]
Genova, Carlo [1 ]
Morbelli, Silvia [2 ]
Rijavec, Erka [1 ]
Barletta, Giulia [1 ]
Biello, Federica [1 ]
Maggioni, Claudia [1 ]
Mennella, Simone [3 ]
Dal Bello, Maria Giovanna [1 ]
Distefano, Roberta [1 ]
Bauckneht, Matteo [2 ]
Cittadini, Giuseppe [3 ]
Merlo, Franco [1 ]
Sambuceti, Gianmario [2 ]
Grossi, Francesco [1 ]
机构：
[1] San Martino Hosp, Natl Inst Canc Res, Lung Canc Unit, Genoa, Italy
[2] San Martino Hosp, Natl Inst Canc Res, Nucl Med, Genoa, Italy
[3] San Martino Hosp, Natl Inst Canc Res, Radiol, Genoa, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
response evaluation; Nivolumab; PERCIST; RECIST;
D O I：
10.1016/j.jtho.2016.11.458
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA10.09
引用
收藏
页码：S401 / S402
页数：2
相关论文
共 50 条
  • [41] Comparison of response evaluation criteria in diffuse large B-cell lymphoma: Lugano versus RECIL, and PERCIST
    Tang, P.
    Tian, R.
    Su, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S303 - S303
  • [42] Comparison of RECIST to Immune Related Response Criteria (irRC) in Patients with NSCLC Treated with Immune-Check Point Inhibitor
    Kim, Hee Kyung
    Lee, Hansang
    Heo, Mi Hwa
    Cho, Jinhyun
    Park, Ju Youn
    Jeong, Su-Mi
    Sun, Jong -Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1294 - S1295
  • [43] The immunocytokine L19-TNF eradicates sarcomas in combination with chemotherapy agents or with immune check-point inhibitors
    Corbellari, Riccardo
    Nadal, Lisa
    Villa, Alessandra
    Neri, Dario
    De Luca, Roberto
    ANTI-CANCER DRUGS, 2020, 31 (08) : 799 - 805
  • [44] Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer
    Genova, Carlo
    Rossi, Giovanni
    Rijavec, Erika
    Biello, Federica
    Barletta, Giulia
    Tagliamento, Marco
    Grossi, Francesco
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (05) : 573 - 585
  • [45] 18-FDG PET-CT DIAGNOSTIC VALUE IN IMMUNE CHECK-POINT INHIBITOR INDUCED MYOSITIS
    Mensi, Samy
    Chassepot, Horstense
    Kharroubi, Dris
    Plomp, Lotta
    Abbar, Baptiste
    Kas, Aurelie
    Spano, Jean-Philippe
    Leonard-Louis, Sarah
    Seilhean, Danielle
    Benveniste, Olivier
    Salem, Joe-Elie
    Allenbach, Yves
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (02) : 477 - 477
  • [46] Evaluation of treatment response by Hopkins criteria on18F FDG PET-CT in patients of non-small cell lung cancer and its comparison with PERCIST response criteria
    Dang, Shreya
    Shivdasani, Divya
    Pereira, Melvika
    Singh, Natasha
    Rungta, Rachita
    Roy, Debdip
    Kesariya, Jugal
    NUCLEAR MEDICINE COMMUNICATIONS, 2023, 44 (11) : 1038 - 1045
  • [47] Preclinical evaluation of novel immune cell therapies, check point inhibitors, and immune cell engagers in humanized mouse models
    Stecklum, Maria
    Wulf-Goldenberg, Annika
    Brzezicha, Bernadette
    Alcaniz, Joshua
    Smits, Glenn
    Walther, Wolfgang
    Hoffmann, Jens
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [48] Humanized mouse models for the preclinical evaluation of novel immune cell therapies, check point inhibitors, and immune cell engagers
    Stecklum, Maria
    Wulf-Goldenberg, Annika
    Alcaniz, Joshua
    Brzezicha, Bernadette
    Wolfgang, Walther
    Hoffmann, Jens
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 222 - 223
  • [49] Neurologic Immune-related Adverse Events Associated with Check-point Inhibitors: A Case Study and Systematic Review of the Literature
    Juster-Switlyk, Kelsey
    Johnson, Nicholas
    NEUROLOGY, 2018, 90
  • [50] Impact of Nutritional Status on Neutrophil-to-Lymphocyte Ratio as a Predictor of Efficacy and Adverse Events of Immune Check-Point Inhibitors
    Sue, Masahiko
    Takeuchi, Yasuto
    Hirata, Shoichiro
    Takaki, Akinobu
    Otsuka, Motoyuki
    CANCERS, 2024, 16 (10)
12345